The global liver disease treatment market reached a value of US$ 20.83 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 30.91 Billion by 2027 exhibiting a CAGR of 6.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

The liver is a vital organ of the human body that performs significant functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining an adequate balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases, and genetic disorders are some common liver diseases. These diseases are commonly caused by infections, genetics, obesity, diabetes, and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. Liver disease treatment aids in the excretion of cholesterol and hormones, increases bile production and enzyme activation.

Liver Disease Treatment Market Trends:
The rising geriatric population, which is suspetible to various chronic ailments, including liver disease, across the globe is one of the prime factors driving the growth of the market. The changing dietary patterns and sedentary lifestyles are boosting the market growth. Additionally, the increasing prevalence of fatty liver disease due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes is favoring the market growth. Moreover, various technological advancements, such as the development of the bioartificial liver, are providing an impetus to the market growth. It utilizes regenerated liver cells to replace liver functions and is widely used for acute liver failure patients. In line with this, the rapid adoption of antiviral drugs as they are safe and effective, assist in suppressing the hepatitis B virus, and help in reducing the risk of developing cirrhosis and hepatocellular carcinoma, is positively impacting the market growth. Apart from this, increasing research and development (R&D) activities, significant growth in the healthcare industry, and the implementation of various government initiatives to promote public health are creating a positive outlook for the market.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global liver disease treatment market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on treatment type, disease type and end user.

Breakup by Treatment Type:

Antiviral Drugs
Immunosuppressants
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy

Breakup by Disease Type:

Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others

Breakup by End User:

Hospitals
Ambulatory Surgical Centers
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Viatris Inc. Key Questions Answered in This Report:
How has the global liver disease treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global liver disease treatment market?
What are the key regional markets?
What is the breakup of the market based on the treatment type?
What is the breakup of the market based on the disease type?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global liver disease treatment market and who are the key players?
What is the degree of competition in the industry?